New insights into the management of differentiated thyroid carcinoma in children and adolescents (Review)

被引:22
作者
Zanella, Andre B. [1 ]
Scheffel, Rafael Selbach [1 ,2 ]
Weinert, Leticia [3 ]
Dora, Jose Miguel [1 ]
Maia, Ana Luiza [1 ]
机构
[1] Hosp Clin Porto Alegre, Thyroid Unit, BR-90035003 Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Pharmacol, BR-90035003 Porto Alegre, RS, Brazil
[3] Univ Fed Pelotas, Hosp Escola, Div Endocrine, BR-96160000 Pelotas, RS, Brazil
关键词
differentiated thyroid carcinoma; paediatric; review; risk stratification; DYNAMIC RISK STRATIFICATION; TERT PROMOTER MUTATIONS; BRAF V600E MUTATION; PROGNOSTIC-FACTORS; SERUM THYROGLOBULIN; FUSION ONCOGENES; PULMONARY METASTASES; INITIAL THERAPY; I-131; THERAPY; PAPILLARY;
D O I
10.3892/ijo.2021.5193
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Differentiated thyroid carcinoma (DTC) is the most common malignant neoplasm of the endocrine system. In children and adolescents, DTC usually presents as a more aggressive disease than in the adult population, but patients often have a favourable prognosis, even in cases of advanced disease. Nevertheless, certain patients have persistent or recurrent disease leading to increased morbidity. A significant challenge in the management of DTC is identifying the subgroup of patients with a high risk of unfavourable outcomes. Prognostic factors related to the patient, tumour, and stratification systems (Tumor-Node-Metastasis/American Joint Committee on Cancer, American Thyroid Association risk classification and dynamic risk stratification) are used in an attempt to identify the individuals at increased risk. In the present review, the current risk classification systems applied for paediatric thyroid cancer are discussed, highlighting the major differences between paediatric and adult DTC in pathophysiology, clinical presentation and long-term outcomes. In recent years, genetic markers have also been proposed as prognostic factors for children and adolescents with DTC. Advances in the understanding of the molecular profile of paediatric DTC may aid individualized management, potentially improving diagnosis and treatment. This review article aims to critically review and update the current concepts on DTC management in children and adolescents, with an emphasis on clinical presentation, treatment, risk assessment, follow-up and future perspectives.
引用
收藏
页数:11
相关论文
共 96 条
[1]   Integrated Genomic Characterization of Papillary Thyroid Carcinoma [J].
Agrawal, Nishant ;
Akbani, Rehan ;
Aksoy, B. Arman ;
Ally, Adrian ;
Arachchi, Harindra ;
Asa, Sylvia L. ;
Auman, J. Todd ;
Balasundaram, Miruna ;
Balu, Saianand ;
Baylin, Stephen B. ;
Behera, Madhusmita ;
Bernard, Brady ;
Beroukhim, Rameen ;
Bishop, Justin A. ;
Black, Aaron D. ;
Bodenheimer, Tom ;
Boice, Lori ;
Bootwalla, Moiz S. ;
Bowen, Jay ;
Bowlby, Reanne ;
Bristow, Christopher A. ;
Brookens, Robin ;
Brooks, Denise ;
Bryant, Robert ;
Buda, Elizabeth ;
Butterfield, Yaron S. N. ;
Carling, Tobias ;
Carlsen, Rebecca ;
Carter, Scott L. ;
Carty, Sally E. ;
Chan, Timothy A. ;
Chen, Amy Y. ;
Cherniack, Andrew D. ;
Cheung, Dorothy ;
Chin, Lynda ;
Cho, Juok ;
Chu, Andy ;
Chuah, Eric ;
Cibulskis, Kristian ;
Ciriello, Giovanni ;
Clarke, Amanda ;
Clayman, Gary L. ;
Cope, Leslie ;
Copland, John A. ;
Covington, Kyle ;
Danilova, Ludmila ;
Davidsen, Tanja ;
Demchok, John A. ;
DiCara, Daniel ;
Dhalla, Noreen .
CELL, 2014, 159 (03) :676-690
[2]   Single Point Mutations in Pediatric Differentiated Thyroid Cancer [J].
Alzahrani, Ali S. ;
Murugan, Avaniyapuram Kannan ;
Qasem, Ebtesam ;
Alswailem, Meshael ;
Al-Hindi, Hindi ;
Shi, Yufei .
THYROID, 2017, 27 (02) :189-196
[3]   Uncommon TERT Promoter Mutations in Pediatric Thyroid Cancer [J].
Alzahrani, Ali S. ;
Qasem, Ebtesam ;
Murugan, Avaniyapuram Kannan ;
Al-Hindi, Hindi N. ;
AlKhafaji, Dania ;
Almohanna, Mai ;
Xing, Mingzhao ;
Alhomaidah, Doha ;
AlSwailem, Meshael .
THYROID, 2016, 26 (02) :235-241
[4]  
[Anonymous], 2006, CANC EPIDEMIOLOGY OL
[5]   Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions [J].
Ballester, Leomar Y. ;
Sarabia, Stephen F. ;
Sayeed, Hadi ;
Patel, Nimesh ;
Baalwa, Joshua ;
Athanassaki, Ioanna ;
Hernandez, Jose A. ;
Fang, Erica ;
Quintanilla, Norma M. ;
Roy, Angshumoy ;
Lopez-Terrada, Dolores H. .
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2016, 19 (02) :94-100
[6]   Molecular Genetics of Thyroid Cancer in Children and Adolescents [J].
Bauer, Andrew J. .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2017, 46 (02) :389-+
[7]   Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].
Brose, Marcia S. ;
Nutting, Christopher M. ;
Jarzab, Barbara ;
Elisei, Rossella ;
Siena, Salvatore ;
Bastholt, Lars ;
de la Fouchardiere, Christelle ;
Pacini, Furio ;
Paschke, Ralf ;
Shong, Young Kee ;
Sherman, Steven I. ;
Smit, Johannes W. A. ;
Chung, John ;
Kappeler, Christian ;
Pena, Carol ;
Molnar, Istvan ;
Schlumberger, Martin J. .
LANCET, 2014, 384 (9940) :319-328
[8]   Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives [J].
Ceolin, Lucieli ;
da Silveira Duval, Marta Amaro ;
Benini, Antonio Felippe ;
Ferreira, Carla Vaz ;
Maia, Ana Luiza .
ENDOCRINE-RELATED CANCER, 2019, 26 (09) :R499-R518
[9]   Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens [J].
Chiovato, L ;
Latrofa, F ;
Braverman, LE ;
Pacini, F ;
Capezzone, M ;
Masserini, L ;
Grasso, L ;
Pinchera, A .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (05) :346-351
[10]   DOES THE METHOD OF MANAGEMENT OF PAPILLARY THYROID-CARCINOMA MAKE A DIFFERENCE IN OUTCOME [J].
DEGROOT, LJ ;
KAPLAN, EL ;
STRAUS, FH ;
SHUKLA, MS .
WORLD JOURNAL OF SURGERY, 1994, 18 (01) :123-130